Pfizer's Xeljanz Is First JAK Positive In PsA But Challenges Ahead
Pfizer’s oral JAK inhibitor Xeljanz is set to lead the JAK inhibitors to market in psoriatic arthritis following positive Phase III data particularly in joint inflammation, but skin findings were disappointing.
You may also be interested in...
Pfizer's JAK inhibitor met its co-primary efficacy endpoints, but US FDA still wants discussion of lack of impact on radiographic progression.
The latest drug development news and highlights from our US FDA Performance Tracker.